“Martin Shkreli is the Donald Trump of drug development,” my friend Frank tells me. “He’s a hedge fund manager who gives hedge fund managers a bad name.” Frank — a chief scientific officer at a biotech company (and whose name has been changed to protect his and his family’s privacy) — is talking to me Tuesday morning, en route to …